Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
How I Manage?
2002:68:4;227-228
PMID: 17656945

Vitiligo

DM Thappa
 Department of Dermatology and STD, JIPMER, Pondicherry, India

Correspondence Address:
D M Thappa
Department of Dermatology and STD, JIPMER, Pondicherry
India
How to cite this article:
Thappa D M. Vitiligo. Indian J Dermatol Venereol Leprol 2002;68:227-228
Copyright: (C)2002 Indian Journal of Dermatology, Venereology, and Leprology

Vitiligo is a common dermatological disorder accounting for nearly 1-2% of our OPD attendance and often poses a therapeutic challenge to the practising dermatologist owing to its prolonged course and varied outcome. The treatment of vitiligo needs to be individualized and thus a tentative plan of management should be decided at the very outset and a realistic goal should be set.

The management of vitiligo begins with a through clinical assessment, which becomes very important in the context of inconclusive investigational parameters. Salient points to be noted in the history include-age, occupation, duration of the disease, history of progression (defined as increase in size of existing lesions or onset of new lesions), treatment history, family history of vitiligo and history of any other associated illness. On examination one should note the sites involved, the extent of involvement, mucosal disease, presence of leucotrichia and Koebnerisation. The patients can be classified depending on the type of vitiligo as:

  • Localized - Focal, segmental, mucosal

After the initial clinical assessment, the patients can be broadly compartmentalized into certain clinical groups to decide on the general line of treatment to be pursued. Thus, most patients would fall into one of the following categories

- Recent onset disease with rapid progression.

  • Generalized, indolently progressive disease.
  • Localized vitiligo
  • Disease warranting surgical management.

The first two groups that is those with actively progressing disease and those with widespread lesions are candidates for systemic medical therapy and we prefer to use systemic steroids in the form of betamethasone oral mini pulse therapy (OMP). After baseline investigations, essential prior to giving oral steroids, oral betamethasone is given in a dose of 5 mg (2.5 mg for children) on two consecutive days each week. The patient is assessed every two weeks initially and monthly thereafter to look for any side effects of steroids and to note any improvement in the lesions. One can wait for upto three months for repigmentation to appear which is usually perifollicular and perilesional. Betamethasone is continued till complete or maximal repigmentation is achieved and therapy should not be discontinued abruptly as the repigmentation may be reversed. Systemic steroids have a dual role in that they suppress the autoimmune damage and halt progression of the disease and thereafter induce pigmentation. In our experience, OMP with betamethasone is not associated with any significant side effects and the only adverse effect that we have encountered is weight gain, though without cushingoid features. Other modality of treatment in these patients would be PuvA therapy though it is advisable to wait till the disease is stabilized and then administer PuvA. Our experience with systemic PUVA is minimal, largely because it requires frequent visits and as most of our patients are manual labourers requiring to work outdoors. However, once the disease is stable, repigmentation of cosmetically important sites can be enhanced with topical PUVA. We use psoralen in 1:10 dilution to be applied thrice weekly on alternate days and weekends off. It should be applied with an applicator or cotton swab to the lesion and the borders should be protected with petrolatum and a sunscreen. After about 30 minutes the lesion is exposed to sunlight beginning with duration of 30 seconds and gradually increasing till erythema appears (usually to a maximum of 5 minutes). The patient is clearly instructed to wash the treated area thereafter with soap and water, apply sunscreen and if feasible wear clothing to cover that site. Repigmentation may take 20-30 exposures to begin with and maximal improvement may take upto 150-300 exposures.

The next group of patients includes those who have localized vitiligo. Focal vitiligo has a good prognosis in that it is more amenable to topical therapy and we have found good results with high potent topical steroids which should be applied once daily with a steroid holiday for at least one week each month to prevent tachyphylaxis. Newer topical steroids like mometasone furoate and fluticasone propionate offer a high safety: efficacy ratio and can be used for longer duration. One can wait for upto three months for repigmentation to appear and thereafter treatment may be continued till maximal repigmentation. The other modality of treatment for focal vitiligo includes topical PUVA which can be used singly or in combination with topical steroids. We have also used topical placental extract, usually in combination with topical steroids and the results have been variable, more often on the lower side of efficacy. The other form of localized vitiligo is segmental vitiligo, which is known to have a better prognosis in that it does not progress inexorably like non-segmental vitiligo. However, response to topical medical therapy in segmental vitiligo is mostly unsatisfactory as would be expected owing to its non-autoimmune etiology and these patients in our experience do best with surgical procedures. Mucosal vitiligo is another form of localized vitiligo with poor response to medical therapy, obviously due to lack of hair follicles acting as pigment reservoirs at these sites. After an initial trial of topical therapy, especially aimed at stabilizing the disease, these patients may also be recruited for surgery.

Patients are recruited for surgical procedures based on certain clinical criteria including

  • Disease, which is stable for at least two years.
  • Failure of appropriate and adequate medical therapy.
  • Localized vitiligo.

Stability of the disease is the most important factor, which must be ensured before undertaking surgical procedures, and it is preferable to put a graft before proceeding with the full procedure. In our center good results have been achieved with punch grafting, blister grafting (especially for mucosal lesions) and tattooing (for smaller areas). Grafting can be followed with application of topical PUVA-SOL once the acute edema of the procedure has subsided to enhance spread of the transplanted pigment.

Vitiligo in children is essentially managed along the same lines as an adult with a few differences. Firstly, it must be remembered that children tend to have a better prognosis and so depending on the extent and activity of the disease, the appropriate treatment should be decided. Most children were found to do fairly well with topical steroids especially those with a high safety index like mometasone furoate and fluticasone propionate. In those children who had widespread disease, we have used oMP with betamethasone at a dose of 2.5mg on two consecutive days each week. Results with this therapy have been largely very satisfactory and contrary to the usual belief, side effects have been noted very rarely.

Another important aspect in the management of vitiligo is to identify the prognostic factors in each patient as this would be essential to decide on the end point of any modality of therapy. In our experience, poor prognostic factors includes history of progression, family history of vitiligo, widespread disease, non-segmental vitiligo, acrofacial vitiligo, mucosal involvement and leukotrichia.

We would also advise that all patients of vitiligo should be given sunscreens antioxidants and options regarding cosmetic camouflage. Finally, the management of vitiligo would not be complete without good counseling, motivation and psychological support to the patient.

Show Sections